The central $8 target is calculated from five current, individually attributable analyst price targets rather than a single published consensus figure. The most recent verified targets include Morgan Stanley at $5.30 (Equal-Weight, August 2026), Bank of America Securities at $6.00 (Neutral, February 2026), Needham at $8.00 (Buy, May 2026), J.P. Morgan at $10.00 (Overweight, April 2026), and UBS at $11.00 (December 2025). These five sum to a mean of $8.06, rounded to $8.
The low-to-high range of $5.30 to $11.00 is unusually wide and signals genuine disagreement. Cautious analysts such as Morgan Stanley emphasize execution risk, heavy cash burn, and the uncertain timeline to a commercial launch. More bullish analysts, led by Needham and J.P. Morgan, argue that the company's AI-enabled discovery platform and early clinical readouts justify a higher valuation. Notably, the direction of revisions in 2026 has been modestly downward, with J.P. Morgan trimming its target from $11 to $10 and Bank of America cutting from $7 to $6, while Needham has held steady at $8.
Recursion Pharmaceuticals, Inc. (RXRX) is a clinical-stage biotechnology company that uses a machine-learning platform to industrialize drug discovery. The stock recently closed near $4.16, within a 52-week range of roughly $2.77 to $7.18. Reaching $8 would require a move of about 92% — a very large increase that would also take the stock above its 52-week high.
The path toward that level would most plausibly be driven by continued positive clinical data, progress toward regulatory discussions for its lead candidate, and renewed investor enthusiasm for AI-enabled biotech. The company reported encouraging Phase 1b/2 results for REC-4881 in familial adenomatous polyposis (FAP), and management has said it plans to engage the U.S. Food and Drug Administration about a potential registration pathway. At the same time, revenue is expected to decline in 2026, and the company remains deeply unprofitable, meaning any sustained rally would have to be supported by pipeline momentum rather than near-term fundamentals.
Several factors could support a higher valuation. REC-4881's positive early data is central to the bull case; J.P. Morgan has highlighted "blockbuster potential," citing peak U.S. sales above $1 billion and a roughly 60% estimated probability of success. REC-617, an oral CDK7 inhibitor in platinum-resistant ovarian cancer, offers a second clinical catalyst. Recursion's partnership model, which management says has generated more than $500 million in milestone payments, and its strategic relationship with Nvidia lend credibility to its AI platform narrative. Broader investor appetite for AI-driven healthcare names could also provide a sentiment tailwind.
The principal obstacles are financial and clinical. Revenue is forecast to fall sharply in 2026, and the company continues to post significant net losses with negative EPS (earnings per share). Recursion has used at-the-market equity offerings, raising the risk of further share dilution that pressures the stock. There is no guarantee that REC-4881 or REC-617 will succeed in later-stage trials or secure regulatory approval, and timelines for a commercial launch remain uncertain. Finally, the wide analyst range — with several firms below $6 — indicates that many professionals do not expect the stock to approach $8 in the near term.
The stock has recovered from its May 2026 low near $2.77 and trades above its 50-day and 200-day moving averages, indicating improving near-term momentum. Key resistance sits around the 52-week high of $7.18, followed by the psychological $8 level. On the downside, support is visible in the $3.50-to-$3.65 zone, with the 52-week low near $2.77 serving as a deeper floor. Because the $8 target sits just above the prior high, it represents a breakout level rather than a return to previously traded territory.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may apply different assumptions. Investors should watch upcoming earnings and guidance, any analyst revisions, FDA interactions regarding REC-4881's registration pathway, and additional clinical readouts for both REC-4881 and REC-617. Funding activity, including at-the-market offerings, is also important given its impact on share count and valuation.
AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-driven name like RXRX, such tools can help traders spot shifts in trend and momentum more efficiently than manual chart review. Traders can use the signals to discover opportunities, monitor existing positions, and identify changing trends as they develop.
The $8 central target is the average of five verified analyst targets ranging from $5.30 to $11.00. From a recent price near $4.16, reaching that level would demand a very large move of roughly 92% and would push the stock beyond its 52-week high. The strongest supports are positive early data for REC-4881, the promise of AI-driven discovery, and strategic backing from Nvidia; the principal obstacles are declining revenue, persistent losses, dilution risk, and clinical uncertainty. The wide target range reflects meaningful disagreement about how much of that potential is already priced in. Investors should monitor clinical milestones, FDA engagement, funding activity, and analyst revisions before drawing conclusions, with no guarantee that the target will be reached.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To RXRX | 1D Price Change % | ||
|---|---|---|---|---|
| RXRX | 100% | +11.23% | ||
| CRSP - RXRX | 63% Loosely correlated | +2.59% | ||
| PRME - RXRX | 63% Loosely correlated | +15.34% | ||
| ABSI - RXRX | 62% Loosely correlated | +1.60% | ||
| BEAM - RXRX | 58% Loosely correlated | +4.57% | ||
| DNA - RXRX | 57% Loosely correlated | +1.99% | ||
More | ||||